RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & ...
In addition to the new exacerbation data, the indication for Stiolto Respimat has been revised. The Food and Drug Administration (FDA) has approved updated labeling for Stiolto Respimat (tiotropium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results